Chengdu University of

Company snapshot

Chengdu University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Diarrhea-predominant Irritable Bowel Syndrome. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (1).

• 1 active pipeline program(s) linked via ClinicalTrials.gov.
• 1 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Chengdu University of. Not investment advice.

• What is Chengdu University of?

  Chengdu University of is a pharma organization headquartered in CN. Primary therapeutic focus areas include Diarrhea-predominant Irritable Bowel Syndrome. NovaPharmaNews links 1 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, Cl

• Is Chengdu University of publicly traded?

  Chengdu University of appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Chengdu University of develop or market?

  We link 1 drug profile(s) where Chengdu University of is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/chengdu-university-of-traditional-chinese-medicine#company-drugs.

• What are the latest developments for Chengdu University of?

  In the last 12 months our linked public records show 1 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Chengdu University of focus on?

  Chengdu University of focuses on Diarrhea-predominant Irritable Bowel Syndrome based on our analysis of their pipeline programs and drug development activities.